As gun violence continues to soar in U.S. cities, one violence prevention specialist tries to stem the tide of homicides in his hometown.Guest: James "JT" Timpson, Director for Community Partnerships and Safety, Roca Maryland and Roca Impact InstituteRead a full transcript and dig deeper into the issues explored in today's episode: https://tradeoffs.org/2021/07/22/sacrifices-and-small-wins-the-fight-against-rising-gun-violence/Sign up for our weekly newsletter to see what research health policy experts are reading right now, plus recommendations from our staff: bit.ly/tradeoffsnewsletterSupport this type of journalism today, with a gift: https://tradeoffs.org/donateFollow us on Twitter: https://twitter.com/tradeoffspod  See acast.com/privacy for privacy and opt-out information.

Tradeoffs

Sacrifices and Small Wins: The Fight Against Rising Gun Violence

A young woman living with cerebral palsy shares the struggles, fears and silver linings she’s experienced during the pandemic.Guest: Jeiri Flores, disability rights advocateRead a full transcript and dig deeper into the issues explored in today's episode: https://tradeoffs.org/2021/07/15/one-womans-year-surviving-the-pandemic-with-a-disabilitySign up for our weekly newsletter to see what research health policy experts are reading right now, plus recommendations from our staff: bit.ly/tradeoffsnewsletterSupport this type of journalism today, with a gift: https://tradeoffs.org/donateFollow us on Twitter: https://twitter.com/tradeoffspod  See acast.com/privacy for privacy and opt-out information.

One Woman’s Year Surviving the Pandemic with a Disability

A congressional ban on removing anyone from Medicaid is likely to expire early next year. What will happen to people who lose their coverage, and how are states preparing for this unprecedented undertaking?Guests:Sara Rosenbaum, JD, Harold and Jane Hirsh Professor of Health Law and Policy, Milken Institute School of Public Health, George Washington UniversityJami Snyder, Director, AHCCCS Dave Richard, Deputy Secretary, North Carolina MedicaidRead a full transcript and see which states are working ahead to prepare for the end of the public health emergency and state-by-state estimates of how many people could lose coverage on our website: Dig deeper into the issues explored in today's episode: https://tradeoffs.org/2021/07/08/why-millions-could-lose-medicaid-next-year/Sign up for our weekly newsletter to see what research health policy experts are reading right now, plus recommendations from our staff: bit.ly/tradeoffsnewsletterSupport this type of journalism today, with a gift: https://tradeoffs.org/donateFollow us on Twitter: https://twitter.com/tradeoffspod  See acast.com/privacy for privacy and opt-out information.

Why Millions Could Lose Medicaid Next Year

Many cities across the United States are rethinking the role of police in responding to mental health emergencies. Miami-Dade County has spent the last two decades revamping their policing — along with many other aspects of how their criminal justice system treats people in crisis. What lessons have they learned?Guests:Steve Leifman, JD, Associate Administrative Judge, Eleventh Judicial Circuit Court of Florida; Founder, Miami-Dade County Criminal Mental Health ProjectCarol Caraballo, MSW, MPA, LCSW, Vice President of Behavioral Health Services, Thriving Mind South FloridaDig deeper into the issues explored in today's episode: https://tradeoffs.org/2021/07/01/one-countys-20-year-effort-to-decriminalize-mental-illnessSign up for our weekly newsletter to see what research health policy experts are reading right now, plus recommendations from our staff: bit.ly/tradeoffsnewsletterSupport this type of journalism today, with a gift: https://tradeoffs.org/donateFollow us on Twitter: https://twitter.com/tradeoffspod  See acast.com/privacy for privacy and opt-out information.

One County’s 20-Year Effort to Decriminalize Mental Illness

How is the pharmaceutical industry reacting to the FDA’s surprising approval of a controversial Alzheimer’s drug, and what do they make of its $56,000 price tag?This is the last episode in our weeklong series examining the potentially sweeping consequences this drug, known as aducanumab, could have on millions of patients’ lives and billions of dollars in health care spending.Guest:Luke Timmerman, Journalist/Founder, Timmerman ReportExplore the full series and additional resources: https://tradeoffs.org/aducanumabRead a transcript of this episode: Sign up for our weekly newsletter to see what research health policy experts are reading right now, plus recommendations from our staff: bit.ly/tradeoffsnewsletterSupport this type of journalism today, with a gift: https://tradeoffs.org/donateFollow us on Twitter: https://twitter.com/tradeoffspod  See acast.com/privacy for privacy and opt-out information.

The Aducanumab Aftermath: The Industry

A controversial new $56,000 Alzheimer’s drug could wreak financial havoc on insurers, seniors and taxpayers.This episode is part of a special weeklong series examining the potentially sweeping consequences this drug, known as aducanumab, could have on millions of patients’ lives and billions of dollars in health care spending.Guest:Mark Miller, PhD, Executive Vice President for Health Care, Arnold VenturesExplore the full series and additional resources: https://tradeoffs.org/aducanumabRead a transcript of this episode: https://tradeoffs.org/2021/06/24/the-aducanumab-aftermath-the-payer/Sign up for our weekly newsletter to see what research health policy experts are reading right now, plus recommendations from our staff: bit.ly/tradeoffsnewsletterSupport this type of journalism today, with a gift: https://tradeoffs.org/donateFollow us on Twitter: https://twitter.com/tradeoffspod  See acast.com/privacy for privacy and opt-out information.

The Aducanumab Aftermath: The Payer

Desperate to slow her cognitive decline, one patient shares her hopes and concerns about the first new Alzheimer’s drug in nearly 20 years.This episode is part of a special weeklong series examining the potentially sweeping consequences this drug, known as aducanumab, could have on millions of patients’ lives and billions of dollars in health care spending.Guest: Arthena Caston, Alzheimer’s patient and advocateExplore the full series and additional resources: https://tradeoffs.org/aducanumabRead a transcript of this episode: https://tradeoffs.org/2021/06/23/the-aducanumab-aftermath-the-patient/Sign up for our weekly newsletter to see what research health policy experts are reading right now, plus recommendations from our staff: bit.ly/tradeoffsnewsletterSupport this type of journalism today, with a gift: https://tradeoffs.org/donateFollow us on Twitter: https://twitter.com/tradeoffspod  See acast.com/privacy for privacy and opt-out information.

The Aducanumab Aftermath: The Patient

A costly, controversial new Alzheimer’s drug is sending shockwaves through the U.S. health care system. How are doctors grappling with questions about its safety and efficacy? This is the first episode in a special conversation series featuring different people reckoning with the potentially sweeping consequences this drug could have on millions of patients’ lives and billions of dollars in health care spending.Guest: Winston Chiong, MD, PhD, Associate Professor of Neurology, University of California, San FranciscoExplore the full series and additional resources: https://tradeoffs.org/aducanumabRead a transcript of this episode: https://tradeoffs.org/2021/06/22/aducanumab-doctor-transcript/Sign up for our weekly newsletter to see what research health policy experts are reading right now, plus recommendations from our staff: bit.ly/tradeoffsnewsletterSupport this type of journalism today, with a gift: https://tradeoffs.org/donateFollow us on Twitter: https://twitter.com/tradeoffspod  See acast.com/privacy for privacy and opt-out information.

The Aducanumab Aftermath: The Doctor

Health policy experts are kicking off the summer with back-to-back conferences: AcademyHealth's Annual Research Meeting and the 10th Annual Conference of the American Society of Health Economists (ASHEcon). Hop on the Tradeoffs Tours bus for conference tips, stories and exciting research with a conference veteran, Kosali Simon.Guest: Kosali Simon, PhD, Herman B. Wells Endowed Professor, Associate Vice Provost for Health Sciences; Indiana UniversityFind links to the conferences' full agendas and an episode transcript on our website: https://tradeoffs.org/2021/06/17/babies-boats-abstracts-an-insiders-guide-to-health-policy-conferences/Sign up for our weekly newsletter to see what research health policy experts are reading right now, plus recommendations from our staff: bit.ly/tradeoffsnewsletterSupport this type of journalism today, with a gift: https://tradeoffs.org/donateFollow us on Twitter: https://twitter.com/tradeoffspod  See acast.com/privacy for privacy and opt-out information.

Babies, Boats & Abstracts: An Insider's Guide to Health Policy Conferences

The pandemic forced dentists across the country to shut down last spring. We talk with one dentist about what that meant for her business, her patients, and what it’s been like to open back up.Guest: Stacey Van Scoyoc, DDS, General Dentist, Co-Owner, Bloomington Family DentalFind additional resources and a full transcript of today's episode on our website: https://tradeoffs.org/2021/06/10/drilling-into-a-dentists-covid-roller-coaster-ride/Take our short listener survey, and you could win a $50 gift card! bit.ly/TradeoffsSurveySign up for our weekly newsletter to see what research health policy experts are reading right now, plus recommendations from our staff: bit.ly/tradeoffsnewsletterSupport this type of journalism today, with a gift: https://tradeoffs.org/donateFollow us on Twitter: https://twitter.com/tradeoffspod  See acast.com/privacy for privacy and opt-out information.

Drilling Into a Dentist's COVID Roller Coaster Ride

The U.S. Food and Drug Administration faces a costly and consequential decision over whether to approve a controversial new Alzheimer’s drug.Guest:Caleb Alexander, Professor of Epidemiology and Medicine, Johns Hopkins Bloomberg School of Public HealthView the transcript for today's episode: https://tradeoffs.org/2021/06/03/the-fdas-pressure-packed-alzheimers-drug-decisionTake our short listener survey, and you could win a $50 gift card! bit.ly/TradeoffsSurveySign up for our weekly newsletter to see what research health policy experts are reading right now, plus recommendations from our staff: bit.ly/tradeoffsnewsletterSupport this type of journalism today, with a gift: https://tradeoffs.org/donateFollow us on Twitter: https://twitter.com/tradeoffspod  See acast.com/privacy for privacy and opt-out information.

The FDA’s Pressure-Packed Alzheimer’s Drug Decision

New national guidelines say millions more Americans should get screened for lung cancer. The test can save lives, but it's inaccessible to many and harmful to some. How should we balance the promise and perils of lung cancer screening?Guests:Otis Brawley, MD, Professor of Oncology, Johns Hopkins University School of MedicineLisa Carter-Harris, PhD, APRN, Behavioral Scientist and Adult Nurse Practitioner, Memorial Sloan Kettering Cancer CenterCherie Erkmen, MD, Professor of Thoracic Surgery and Director, Lung Cancer Screening Program, Temple UniversityElla Kazerooni, MD, Professor of Radiology, University of MichiganIda Pittman, lung cancer patient, Temple University Hospital Helena Price, Ida’s cousin and health care advocateGerard Silvestri, MD, Professor of Pulmonology, Medical University of South CarolinaDig deeper into the research and tradeoffs of lung cancer screening on our website: https://tradeoffs.org/2021/05/27/catching-americas-top-cancer-killer/Take our short listener survey, and you could win a $50 gift card! bit.ly/TradeoffsSurveySign up for our weekly newsletter to see what research health policy experts are reading right now, plus recommendations from our staff: bit.ly/tradeoffsnewsletterSupport this type of journalism today, with a gift: https://tradeoffs.org/donateFollow us on Twitter: https://twitter.com/tradeoffspod  See acast.com/privacy for privacy and opt-out information.

Catching America’s Top Cancer Killer

With about one-third of Americans still not convinced they need to be vaccinated for COVID-19, many employers are debating whether to require their workers to get vaccinated. We dig into the research to help employers weigh the pros and cons.Guests:Sayeh Nikpay, PhD; Tradeoffs Contributing Research Editor; Associate Professor of Health Policy and Management, University of MinnesotaCorey White, PhD; Assistant Professor of Economics; Cal Poly, San Luis ObispoBrandyn Churchill, PhD Candidate, Vanderbilt UniversityLearn more about Corey and Brandyn's research and the pros and cons of employer mandates on our website: https://tradeoffs.org/2021/05/20/calling-the-shots-should-employers-mandate-covid-vaccines/Take our short listener survey, and you could win a $50 gift card! bit.ly/TradeoffsSurveySign up for our weekly newsletter to see what research health policy experts are reading right now, plus recommendations from our staff: bit.ly/tradeoffsnewsletterSupport this type of journalism today, with a gift: https://tradeoffs.org/donateFollow us on Twitter: https://twitter.com/tradeoffspod  See acast.com/privacy for privacy and opt-out information.

Calling the Shots: Should Employers Mandate COVID Vaccines?

In this special live episode, policy experts and employers debate the best way to improve the health insurance that 150 million Americans get through work. This session was part of “The Promise of Health Reform and a Public Option in a Biden Administration,” a virtual conference put on by the Leonard Davis Institute of Health Economics at the University of Pennsylvania and United States of Care.Guests:Brian Blase, PhD, CEO, Blase Policy Strategies; Senior Fellow, Galen Institute; Senior Fellow, Foundation for Government AccountabilitySuzanne Delbanco, PhD, MPH, Executive Director, Catalyst for Payment ReformAllison Hoffman, JD, Professor of Law and LDI Senior Fellow, University of PennsylvaniaShaundell Newsome, Founder, Sumnu Marketing; Co-Chair, Small Business for America’s FutureSheila Savageau, U.S. Health Care Leader, General Motors (edited) Dig deeper into the research and tradeoffs of integrated care on our website: https://tradeoffs.org/2021/05/13/3-employers-2-wonks-and-1-health-insurance-mess/LISTEN BACK to our recent episode how what other employers are managing the cost of health care: https://tradeoffs.org/2021/02/18/the-high-price-of-lowering-health-costs/Sign up for our weekly newsletter to see what research health policy experts are reading right now, plus recommendations from our staff: bit.ly/tradeoffsnewsletterSupport this type of journalism today, with a gift: https://tradeoffs.org/donateFollow us on Twitter: https://twitter.com/tradeoffspod  See acast.com/privacy for privacy and opt-out information.

3 Employers, 2 Wonks and 1 Health Insurance Mess (LIVE!)

Racism against people of Asian descent is not a new problem, but it’s been exacerbated lately by politicians using racist rhetoric to describe the coronavirus. Asians in America are now facing a dual pandemic: a heightened fear of racist abuse, from verbal slurs to physical assault, on top of all the anxiety of living through COVID-19. A conversation from our colleagues at The Dose.Guests:Shanoor Servai, MPP, Researcher, Writer and Lead Podcast Producer; The Commonwealth FundVivian Shaw, PhD, College Fellow, Department of Sociology at Harvard University; Lead Researcher, AAPI COVID-19 ProjectSusanna Park, PhD Candidate in Global Health, Oregon State UniversityRead a full transcript and learn more information about the AAPI COVID-19 project on our website: https://tradeoffs.org/2021/05/06/presenting-the-dose-asian-americans-and-the-dual-pandemic/Sign up for our weekly newsletter to see what research health policy experts are reading right now, plus recommendations from our staff: bit.ly/tradeoffsnewsletterSupport this type of journalism today, with a gift: https://tradeoffs.org/donateFollow us on Twitter: https://twitter.com/tradeoffspod  See acast.com/privacy for privacy and opt-out information.

Presenting The Dose: Asian Americans and the Dual Pandemic

When it comes to fixing America's costly and complicated health care system, the truth is: there are no silver bullets, no cure-alls. There are only Tradeoffs. Long-time health care reporter Dan Gorenstein hosts an examination of health care, policy, and people...new episodes every other Wednesday.